Compares 2-dose and 3-dose hepatitis B vaccine schedules in people with cirrhosis
Tests 2-dose versus 3-dose Heplisav B vaccine in adults with cirrhosis.
Key facts
- Who runs it
- Mercy Medical Center
- Where
- Baltimore, United StatesSee the site
- Trial code
- Registry title
- Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
- Status
- Recruiting
- Phase
- Phase 4
- People taking part
- 200 people, planned
- Started
- 14 Sept 2020
- Expected to end
- 1 Dec 2028
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Heplisav-B Injectable Product, 2-dose regimen
- Heplisav-B Injectable Product, 3-dose regimen
- Record updated
- 19 November 2024
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with cirrhosis who are not immune to hepatitis B. It compares a 2-dose and a 3-dose Heplisav B vaccine schedule.
- Age
- More than 18 years old
- Sex
- All sexes can join
- Disease stage
- Cirrhosis of the liver
- Biomarker or test result
- No immunity against hepatitis B: anti-HBs titer < 10 mIU/ml
Main reasons for not taking part
- Serious allergic reaction to a prior dose of the hepatitis B vaccine, to a vaccine component, or to yeast
- Previous exposure to hepatitis B
- Liver transplant already done
- Less than 18 years old
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- All the cirrhosis patients more than 18 years old presented to the hepatology clinic in Mercy Medical Center between 09/2020 and 07/2021 who do not have immunity against Hepatitis B (defined as anti-HBs titer < 10 mIU/ml) will be recruited
Who cannot take part
- Anyone who has had a serious allergic reaction to a prior dose of the hepatitis B vaccine, a component of the hepatitis B vaccine, or yeast should not receive the hepatitis B vaccine
- Those who had previous exposure to hepatitis B
- Post liver transplant patients
- Less than 18 years old
Where in United States
- Mercy Medical CenterBaltimore, United StatesContact: CHAU TO, MDTaking people
About the trial
What the trial wants to find out
Investigators want to compare the seroconversion rates between two-dose and three-dose regimens of the hepatitis B vaccine (Heplisav B) among patients with cirrhosis, a randomized prospective study.
The 4 groups in the trial
- Cirrhosis, 3-dose regimenTreatment being tested
Investigators will randomize the patient in the cirrhotic group to receive a 3-dose regimen of Heplisav-B.
Treatment: Heplisav-B Injectable Product, 3-dose regimen
- Cirrhosis, 2-dose regimenExisting treatment, for comparison
Investigators will randomize the patient in the cirrhotic group to receive a 2-dose regimen of Heplisav-B.
Treatment: Heplisav-B Injectable Product, 2-dose regimen
- Non cirrhosis, 3-dose regimenTreatment being tested
Investigators will randomize the patient in the noncirrhotic group to receive a 3-dose regimen of Heplisav-B.
Treatment: Heplisav-B Injectable Product, 3-dose regimen
- Non cirrhosis, 2-dose regimenExisting treatment, for comparison
Investigators will randomize the patient in the noncirrhotic group to receive a 2-dose regimen of Heplisav-B.
Treatment: Heplisav-B Injectable Product, 2-dose regimen
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Comparison the Seroconversion Rate Between Two-dose and Three-dose Regimens of Heplisav B Among Patients With Cirrhosis, a Randomized-control Prospective Study.
- Plain-language title
- Compares 2-dose and 3-dose hepatitis B vaccine schedules in people with cirrhosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 19 November 2024